• כרטיס רופא והטבות
  • אתרי הר"י
  • צרו קשר
  • פעולות מהירות
  • עברית (HE)
  • מה תרצו למצוא?

        תוצאת חיפוש

        אוקטובר 2001

        רוברט דרגו, יהודה עדות
        עמ'

        רוברט דרגו, יהודה עדות

         

        המח' לרפואה פנימית ג' מרכז רפואי רמב"ם והטכניון, הפקולטה לרפואה, חיפה

         

        בשנת 1956 דיווח Edmondson על נערה בת 14 שלקתה בשאת בכבד; בבדיקה היסטופתולוגית של השאת שנכרתה, הודגמו מימצאים המצביעים על קאצינומה הפטוצלולרית של הכבד (קה"צ), שכונה בשמות שונים:

         

        1) hepatocellular carcinoma with laminar fibrosis.

        2) hepatocellular carcinoma with polygonal cell type and fibrous stroma.

        3) Oncocytic hepatocellular tumor.

        4) Eosinophilic hepatocellular carcinoma with lamelar fibrosis.

         

        המונח המקובל היום הוא קאצינומה הפטוצלולרית לייפתית-לוחיתית של הכבד (fibrolamellar hepatocellular carcinoma) להלן קפל"ה. בספרות האנגלית דווחו על כ-150 חולים שלקו בקפל"ה. המטרות בסקירה הנוכחית הן:

         

        1) להעלות את מודעות הקלינאי לסוג זה של שאת.

        2) לסכם את המידע העדכני בנושא מבחינה אפידמיולוגית, היסטופתולוגית, הסתמנות קלינית, אמצעי דימות אבחנתיים, טיפול, מעקב ותחזית.

        יוני 2000

        דוד פרג, שלמה בכר, אלכסנדר בטלר, ולנטינה בויקו, שמואל גוטליב ויהונתן ליאור
        עמ'

        Thrombolytic Therapy or Primary Coronary Angioplasty in Acute Myocardial Infarction?

         

        David Pereg, Shlomo Behar, Alexander Battler, Valentina Boyko, Shmuel Gottlieb, Jonathan Leor: Israel Thrombolytic Survey Group

         

        Cardiology Division, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba; Neufeld Cardiac Research Institute, Tel Hashomer and Tel Aviv University; and Cardiology Dept., Rabin Medical Center, Petah Tikva

         

        There has been continuous debate over the superiority of primary percutaneous, transluminal, coronary angioplasty (PTCA) over thrombolysis for acute myocardial infarction (AMI). It was questioned whether this advantage of primary PTCA reported in selected populations by experienced centers can be replicated in our clinical practice.

        We compared demographic and clinical variables, therapies and outcome in AMI treated with primary PTCA vs thrombolytic therapy. Clinical and demographic variables of 1,678 unselected AMI patients (admitted January/February and May/July 1996) were analyzed in 16 cardiac care units with on-site catheterization facilities and ability to perform PTCA. Of these 803 (48%) were treated by thrombolysis and 99 (6%) by primary PTCA.

        The prevalence of adverse prognostic variables, such as anterior wall MI, heart failure on admission or during hospital stay, pulmonary edema, and ventricular tachycardia or fibrillation, was higher in the PTCA group. The 7-day, 30-day and 1-year mortality rates were similar in the 2 groups: 4%, 7.2% and 12.8%, respectively, in the PTCA group and 5%, 7.2% and 11.1% in the thrombolysis group. There was a trend toward lower mortality in subgroups of high-risk patients: those with heart failure on admission (Killip class >1), the elderly (>65 years), and those with previous MI treated with PTCA. After adjusting for confounders, treatment with primary PTCA was not found to be associated with lower mortality.

        Only a small proportion of AMI patients in Israel were treated with primary PTCA in 1996. The frequency of adverse prognostic factors among them was higher but their short and long term outcomes were similar to those of high risk patients treated with thrombolysis.

        פברואר 2000

        הקבוצה הישראלית לרישום סתב"א
        עמ'

        Incidence of Insulin Dependent Diabetes in Youth in Israel 


        Israel IDDM Registry Study Group

         

        Recent reports from different countries have shown an increasing incidence of insulin-dependent diabetes mellitus (IDDM, type I diabetes). In Israel, several surveys of the incidence of IDDM have been conducted. During 1996, a national juvenile diabetes register was founded by specialists in endocrinology, and the Israel Center for Disease Control (ICDC).

        This is the first report of the national incidence of IDDM in the 0-17 year age group in Israel. New cases of juvenile diabetes were reported using an anonymous form. The ICDC was responsible for data collection, control and statistical analyses.

        During 1997, 162 new cases of diabetes mellitus were reported in the age group 0-17, 154 of them diagnosed as IDDM. The annual incidence in the total population of Israel in 1997 was 7.7/100,000. Age-specific incidence was 7.3/100,000 in boys and 8.1 in girls. A family history of IDDM was found in 14.3% of the cases. Incidence was higher for Jews (9.2/100,000) than Arabs (3.6/100,000). Among Jews, children whose fathers were born in Yemen had the highest incidence and those born to fathers born in Israel the lowest incidence.

        IDDM incidence rates for 1997 are higher than reported in previous surveys. It will be possible to draw conclusions regarding possible trends in incidence from data to be gathered in the next few years.

        ינואר 1999

        א' אורנוי, ס' שכטמן וג' ארנון
        עמ'

        The Israel Teratogen Information Service: A 10-Year Report 


        A. Ornoy, S. Shechtman, J. Arnon

         

        Hebrew University - Hadassah Medical School and Israel Ministry of Health, Jerusalem

         

        The Israel Teratogen Information Service (TIS) was established 10 years ago with the help of the Ministry of Health and the Hebrew University-Hadassah Medical School. During these 10 years we have had 20,631 calls. We describe the results of our experience in counseling.

        There was a gradual increase in the number of calls, which in 1997 reached 4,447. Most calls (84.5%) were during pregnancy, while 12% were prior to pregnancy. In 75.7% the calls were due to drug exposure during pregnancy; 10.9% were due to exposure to X-rays; there was maternal infection in 6.6% and in 5% immunization during pregnancy. The callers were: physicians in 46.6%, nurses 18.9%, pregnant women 39.5%, and 4.8% others.

        In 76.6% there was no additional risk to the embryo or fetus and in 17.4% there was a small additional risk of less than 1%; a significant additional risk to the fetus was expected in only 6%. In 3625 pregnant women with known outcome there were 8.9% spontaneous and 9.2% induced abortions. Of the 2968 live-born children, 2.3% were malformed, a rate similar to that among controls.

        The information provided by the TIS alleviated the fears most pregnant women have, and reduced unnecessary terminations of pregnancy planned because of unjustified fear of the teratogenic effects of agents to which women were exposed. It reduced the number of children born with congenital anomalies, since pregnancies were interrupted whenever there was a high risk for congenital anomalies.

        הבהרה משפטית: כל נושא המופיע באתר זה נועד להשכלה בלבד ואין לראות בו ייעוץ רפואי או משפטי. אין הר"י אחראית לתוכן המתפרסם באתר זה ולכל נזק שעלול להיגרם. כל הזכויות על המידע באתר שייכות להסתדרות הרפואית בישראל. מדיניות פרטיות
        כתובתנו: ז'בוטינסקי 35 רמת גן, בניין התאומים 2 קומות 10-11, ת.ד. 3566, מיקוד 5213604. טלפון: 03-6100444, פקס: 03-5753303